ECOR
electroCore, Inc. NASDAQ Listed Jun 22, 2018$8.43
-3.10%
vs $8.70
Mkt Cap $71.5M
52w Low $4.31
68.2% of range
52w High $10.35
50d MA $7.48
200d MA $6.09
P/E (TTM)
-5.1x
EV/EBITDA
—
P/B
—
Debt/Equity
-5.5x
ROE
817.2%
P/FCF
-8.7x
RSI (14)
40.30
ATR (14)
$1.07
Beta
0.60
50d MA
$7.48
200d MA
$6.09
Avg Volume
150.2K
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
200 Forge Way · Rockaway, NJ 07866 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -0.59 | -0.59 | +0.0% | 6.66 | -1.1% | -5.9% | +2.2% | +3.1% | +1.4% | -5.7% | — |
| Mar 19, 2026 | AMC | -0.35 | -0.34 | +2.9% | 6.56 | -2.3% | -4.7% | -1.9% | +0.7% | +8.4% | -10.0% | — |
| Nov 5, 2025 | AMC | -0.36 | -0.40 | -11.1% | 4.74 | +4.9% | +23.2% | -0.2% | +6.7% | +1.3% | -3.8% | — |
| Aug 6, 2025 | AMC | -0.32 | -0.35 | -9.4% | 6.93 | -17.6% | -29.1% | -5.9% | -6.7% | +3.9% | +14.7% | — |
| May 7, 2025 | AMC | -0.56 | -0.47 | +16.1% | 6.81 | -14.8% | -23.8% | -10.4% | +3.7% | -2.1% | -2.3% | — |
| Mar 12, 2025 | AMC | -0.34 | -0.40 | -17.6% | 13.00 | -9.8% | -26.5% | -10.4% | -3.5% | +1.5% | -4.4% | — |
| Nov 13, 2024 | AMC | -0.29 | -0.31 | -6.9% | 13.40 | -12.3% | +1.5% | -19.6% | -11.8% | +4.6% | -1.5% | — |
| Aug 7, 2024 | AMC | -0.39 | -0.38 | +2.6% | 6.10 | +3.8% | -1.3% | -6.1% | +7.3% | -2.8% | +1.4% | — |
| May 8, 2024 | AMC | -0.50 | -0.53 | -6.0% | 7.24 | +1.4% | -5.4% | -0.1% | +6.0% | +3.4% | -1.3% | — |
| Mar 13, 2024 | AMC | -0.55 | -0.61 | -10.9% | 6.45 | -3.7% | -5.6% | +9.0% | +5.4% | -1.0% | -8.1% | — |
| Nov 8, 2023 | AMC | -0.64 | -0.68 | -6.2% | 5.77 | +9.4% | +2.8% | -3.2% | -2.4% | +3.2% | +7.8% | — |
| Aug 9, 2023 | AMC | -1.00 | -1.03 | -3.0% | 5.43 | -5.0% | -8.8% | -0.8% | +0.2% | +3.3% | -6.1% | — |
| May 3, 2023 | AMC | -1.00 | -1.24 | -24.0% | 6.00 | -0.7% | -5.0% | +1.1% | +5.0% | -0.5% | -4.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.47 | $7.41 | -0.8% | +9.1% | -3.3% | -8.0% | -2.1% | -6.2% |
| Mar 13 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $13.00 | $11.73 | -9.8% | -26.5% | -10.4% | -3.5% | +1.5% | -4.4% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.00 | $11.73 | -9.8% | -26.5% | -10.4% | -3.5% | +1.5% | -4.4% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.93 | $14.73 | +5.7% | +11.1% | -6.1% | +5.2% | +14.7% | -7.2% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.45 | $6.21 | -3.7% | -5.6% | +9.0% | +5.4% | -1.0% | -8.1% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.63 | $6.97 | +5.1% | +9.0% | +2.1% | +0.8% | +1.5% | -1.5% |
| Nov 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.77 | $6.31 | +9.4% | +2.8% | -3.2% | -2.4% | +3.2% | +7.8% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.43 | $5.16 | -5.0% | -8.8% | -0.8% | +0.2% | +3.3% | -6.1% |
| May 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.00 | $5.96 | -0.7% | -5.0% | +1.1% | +5.0% | -0.5% | -4.8% |
| Apr 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.91 | $7.16 | +3.6% | -4.6% | +3.5% | -2.1% | +2.5% | -1.8% |
| Jan 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.36 | $12.00 | -2.9% | -16.3% | -2.7% | -7.9% | +5.4% | +4.7% |
| Aug 14 | BTIG | Upgrade | Neutral → Buy | — | $33.90 | $34.80 | +2.7% | +0.4% | -5.3% | -1.9% | -5.2% | -3.5% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.90 | $34.80 | +2.7% | +0.4% | -5.3% | -1.9% | -5.2% | -3.5% |
| Mar 24 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $7.05 | $6.90 | -2.1% | -4.3% | -4.4% | +8.2% | -13.2% | +199.5% |
| Nov 14 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $27.75 | $22.05 | -20.5% | -20.0% | +6.8% | -13.3% | +13.9% | -3.2% |
| Nov 14 | JMP Securities | Downgrade | Outperform → Market Perform | — | $27.75 | $22.05 | -20.5% | -20.0% | +6.8% | -13.3% | +13.9% | -3.2% |
| May 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $79.95 | $75.75 | -5.3% | -29.6% | +1.1% | -20.8% | +4.0% | +0.3% |
| May 15 | BTIG Research | Downgrade | Buy → Neutral | — | $79.95 | $75.75 | -5.3% | -29.6% | +1.1% | -20.8% | +4.0% | +0.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 28, 2026 | Lev Joshua S.Off | CFO and Interim President | Sell | 6,667 | $9.00 | $60K | 84,889 | +6.05% | -12.27% |
| May 21, 2026 | Errico Thomas J.Dir | — | Buy | 9,992 | $5.99 | $60K | 360,071 | +3.70% | -8.70% |
8-K · 2.02
!! High
electroCore, Inc. -- 8-K 2.02: Earnings Results
electroCore reported earnings results showing operational performance changes, though specific financial metrics require reviewing the attached press release exhibit for investor impact assessment.
May 6
8-K
Unknown — 8-K Filing
ElectroCore's 27% revenue growth to $32.0 million in 2025 demonstrates strong market traction for its neuromodulation devices, making it attractive to investors seeking biotech exposure with proven commercial momentum.
Mar 19
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 7
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Federated Hermes SDG Engagement Equity Fund | 923,747 | $2M | Jan 2026 |
| 2 | Avantis International Small Cap Value ETF | 928,253 | $2M | Feb 2026 |
| 3 | Avantis International Equity ETF | 314,766 | $607K | Feb 2026 |
| 4 | Avantis International Small Cap Value Fund | 39,689 | $77K | Feb 2026 |
| 5 | Avantis International Equity Fund | 24,204 | $47K | Feb 2026 |
| 6 | Avantis Responsible International Equity ETF | 13,088 | $25K | Feb 2026 |
| 7 | Avantis International Small Cap Equity ETF | 8,911 | $17K | Feb 2026 |
Valuation
Market Cap
$71.5M
Enterprise Value
$66.5M
P/E (TTM)
-5.11x
Forward P/E
—
PEG Ratio
-0.72x
P/B
—
P/S
2.23x
P/FCF
-8.66x
EV/EBITDA
—
Shares Out
8.5M
Financials (TTM)
Revenue
$32.0M
Net Income
-$14.0M
EBITDA
-$11.5M
Free Cash Flow
-$8.3M
Op Cash Flow
-$8.2M
EPS Basic
$-1.65
EPS Diluted
$-1.65
EPS Forward
$-1.44
Gross Margin
86.8%
Op Margin
-41.1%
Net Margin
-43.6%
Balance Sheet
Total Assets
$18.7M
Total Liab.
$20.4M
Total Equity
-$1.7M
Cash
$11.6M
LT Debt
$6.6M
Book Value/Sh
$-0.20
Debt/Equity
-5.50x
Current Ratio
1.02
Quick Ratio
0.88
Returns & Growth
ROE
817.2%
ROA
-74.8%
ROIC
-170.9%
Rev Growth YoY
+27.2%
EPS Growth YoY
-3.8%
Price Returns
2W
+51.8%
1M
+49.9%
3M
+28.8%
6M
+93.3%
12M
+95.2%
Technicals
52W High
$10.35
52W Low
$4.31
50d MA
$7.48
200d MA
$6.09
RSI (14)
40.30
ATR (14)
$1.07
Beta
0.60
Avg Volume
150K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 6:22am
· Source: financialmodelingprep.com